Condition Guide

Peptides for Erectile Dysfunction

PT-141 activates central melanocortin receptors to drive sexual arousal. Unlike PDE5 inhibitors (Viagra, Cialis), the mechanism is neurogenic rather than vascular.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

How peptides help

PT-141 has been studied in ED and demonstrates efficacy in both responders and non-responders to PDE5 inhibitors. FDA approval is specific to female HSDD; male use is off-label.

Peptides researched for erectile dysfunction

PT-141

Moderate EvidenceL5

Phase II data supports ED efficacy; FDA indication is for HSDD.

56 studies · Melanocortin MC4R Agonism

State of the evidence

Phase II data in ED is positive. FDA approval was pursued only for HSDD due to cardiovascular concerns in the ED male population.

Frequently asked

Is PT-141 approved for men?

Not for ED. FDA approval (as Vyleesi) is for HSDD in premenopausal women. Off-label use in men is common but not FDA-endorsed.

Related conditions

Female Sexual Dysfunction

PT-141 (bremelanotide) is FDA-approved for premenopausal HSDD.

Growth Hormone Deficiency

Growth hormone-releasing peptides that stimulate pulsatile endogenous GH secretion.